Compare Bristol-Myers Squibb Co (BMY) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs DigitalOcean Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.4 (market cap $116.30B), while DigitalOcean Holdings Inc trades at $120.5 (market cap $13.18B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.8× DigitalOcean Holdings Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while DigitalOcean Holdings Inc pays none. Which is the better fit depends on your goals.
| BMY | DOCN | |
|---|---|---|
Market Cap | $116.30B | $13.18B |
Sector | Health | Technology |
52-Week High | $62.37 | $181.29 |
52-Week Low | $42.60 | $25.74 |
Enterprise Value | $152.24B | $13.74B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
DigitalOcean (DOCN) trades at $123.32, down 5.49% today, with bearish technical signals but strong fundamental performance. The company reported record Q2 2026 results with revenue exceeding expectations and significant AI-driven growth. Analyst consensus remains bullish with a $174.80 price target, though technical indicators show selling pressure near-term.
The outlook remains positive given strong AI adoption and enterprise wins, with 63% analyst buy ratings supporting upside potential. Key risks include high valuation multiples and competitive cloud market pressures. The stock's current weakness presents a potential entry point for growth investors seeking AI infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
